Christopher Yea - May 26, 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Development Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
May 26, 2021
Transactions value $
$0
Form type
4
Date filed
5/28/2021, 05:26 PM
Next filing
Aug 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (Right to Buy) Award $0 +60K $0.00 60K May 26, 2021 Common Stock 60K $25.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 4 year period: 1/48th on June 26, 2021, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.